Additionally, in the context of CAR NK cells, antigen loss or heterogeneity observed for patients both in CD19- and BCMA-directed CAR-T cell therapies, may be less critical due to the NK cells’ ability to target a broader spectrum of tumor ligands [13, 14]. The gene discussed is CD19; the disease is neoplasm.